Gagelmann N, Bacigalupo A, Rambaldi A, et al. - The outcomes of haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other transplant types in adults with hematologic cancers were investigated via performing a meta-analysis of 30 studies including 22,974 patients. The use of haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy was related to higher all-cause mortality relative to matched related donors, similar all-cause mortality relative to matched unrelated donors, and decreased all-cause mortality relative to mismatched unrelated donors. Compared with matched unrelated donors, relapse seemed to be raised in lymphoma and similar in acute leukemia. These findings suggest that preference could be given to haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy over transplantations from mismatched unrelated donors.